IngredientesGlucosylceramide (abbreviated GlcCer or GluCer) is systematically classified as a glycosphingolipid — specifically, the simplest mono-hexosylceramide — in which a single glucose sugar is attached via a β-glycosidic bond to a ceramide backbone. It is composed of a ceramide backbone linked to a single glucose moiety via a β-glycosidic bond, occupying a central role in sphingolipid metabolism and cellular homeostasis. Its older synonym, glucocerebroside, remains in use in clinical and biochemical literature; the compound is also designated β-D-glucosyl-N-acylsphingosine or 1-β-D-glucosyl ceramide.
Glucosylceramide (GlcCer) is composed of a long-chain base (LCB) with an amide-linked fatty acid (i.e., ceramide) and a polar head group (i.e., glucose), one class of sphingolipids, and is found naturally in plant-derived foods.
The molecular structure varies considerably depending on the biological source. Soybean GlcCer is comprised primarily (>98%) of ceramide with 4,8-sphingadiene (d18:2Δ4,Δ8) and alpha-hydroxypalmitic acid (h16:0); the remainder had the same backbone with h18:0, h20:0, h22:0, and h24:0 fatty acids. Wheat GlcCer had three major ceramide species — d18:2(Δ4,Δ8) with h16:0, d18:1(Δ8) with h16:0, and d18:2(Δ4,Δ8) with h20:0 — and smaller amounts of other homologs. The predominant bases of GlcCer are d18:2(4t,8c) in rice and maize, d18:2(4t,8t) in soybeans, and d18:1(8c) in wheat and rye.
The most abundant class of sphingolipids in plant tissue are mono-glucosylceramides, which are mostly characterized by a double bond at position 8 on the sphingoid residues and α-hydroxy fatty acids. This structural feature — the Δ8 double bond — distinguishes plant-derived GlcCer from the predominantly sphingosine (d18:1Δ4)-based GlcCer found in mammalian tissues.
Glucosylceramide is a major sphingolipid of plant tissue and, thus, abundant in nature and in dietary food sources. Glucosylceramides are found in various plants, such as rice, konjac, wheat, and pineapple, and ceramides have also been identified in soy sauce lees and citrus peel. Beyond plants, GlcCer has been isolated from fungi, yeast (notably Candida utilis, or torula yeast), and marine organisms. Three homogeneous sphingosine-type glucocerebrosides were isolated from the body walls of the cold-water sea cucumber Cucumaria frondosa.
Much higher concentrations of glucosylceramides are found in pollen than in leaves, with substantial compositional differences. In plant tissues broadly, the fatty acid components are not very different in nature from those in animal tissues, comprising mainly longer-chain saturated and monoenoic acids, with a high proportion being saturated and having a hydroxyl group in position 2.
GlcCer is also present in animal-derived foods. Neutral sphingolipid classes in animal-derived foods such as meats and egg yolk primarily consist of sphingomyelin and also include glucosylceramide and ceramide. Milk and dairy products contain GlcCer and lactosylceramide in addition to sphingomyelin, and they are rich in gangliosides.
A daily Japanese diet has been estimated to contain approximately 50 mg of GlcCer from plant foods such as rice, maize, and other sources, and it is believed that GlcCer consumed in the diet can help prevent certain diseases.
As a dietary supplement, glucosylceramide is commercially available derived from several standardized plant and fungal sources:
Glucosylceramide as a defined chemical entity was not isolated or named in traditional herbal medicine contexts. Originally characterized in the 1920s in the spleens of Gaucher disease patients, GlcCer is now recognized as a key molecule embedded in various cellular membranes including the plasma membrane, Golgi apparatus, endosomes, and lysosomes. Its early history therefore lies in the field of disease biochemistry rather than ethnobotanical use.
The broader food history of its source plants does carry traditional significance. Amorphophallus konjac (Family: Araceae) is a perennial plant commonly known as konjak or konnyaku, and konjac is a traditional food ingredient and medicine used in China, Japan, and South East Asia. However, traditional uses of konjac were attributed to its glucomannan polysaccharide fiber content, not to its sphingolipid fraction, which was not distinguished prior to modern analytical chemistry.
The systematic scientific investigation of dietary GlcCer as a functional food component emerged primarily from Japanese food science in the late 1990s and early 2000s. Around 2000, the use of dietary sphingolipids for the prevention of colon cancer was reported, and in the 2010s, an increase in skin barrier function due to dietary sphingolipids was reported. The research landscape has grown steadily since, with most clinical investigations conducted in Japan.
Glucosylceramide is itself a single lipid class rather than an extract containing multiple distinct active molecules; its bioactivity depends critically on the composition of its ceramide backbone. The major structural variables across sources are:
Synthesized in the Golgi apparatus via glucosylceramide synthase (GCS, also known as UDP-glucose ceramide glucosyltransferase — UGCG), GlcCer serves as the metabolic precursor for more than 90% of mammalian glycosphingolipids (GSLs), including complex gangliosides. These molecules are essential for mammalian development and viability, as evidenced by embryonic lethality in mice lacking UGCG.
The biosynthesis of glucosylceramides is catalyzed by a UDP-glucose:ceramide glucosyltransferase (glucosylceramide synthase, GCS; EC 2.4.1.80), which was originally found in animal tissues. This enzyme catalyzes the transfer of glucose from UDP-glucose to ceramide, leading to the formation of glucosylceramide, and plays a central role in sphingolipid metabolism.
Glucocerebrosidase (also known as acid β-glucosidase) is responsible for the hydrolysis of glucosylceramide to ceramide and glucose; this lysosomal enzyme plays a critical role in the degradation of glycosphingolipids and the recycling of sphingolipid components within the cell.
Glucosylceramide is the precursor for synthesis of the complex glycosphingolipid family of gangliosides, for example the GM3 gangliosides. As the gateway to the hexosylceramide pathway, endogenous GlcCer levels directly regulate the downstream availability of biologically active gangliosides and globosides that modulate cell-surface signaling, membrane raft organization, and inflammatory tone. Beyond its canonical role in glycosylation, GlcCer functions as a discrete signaling lipid, orchestrating critical processes including energy homeostasis, inflammatory responses, and membrane dynamics.
Dietary ceramides and glucosylceramides can be absorbed as intact molecules or, after being hydrolyzed, as free sphingoid bases, which are then resynthesized into ceramides with endogenous non-hydroxy fatty acids. Dietary glycosylceramides are metabolized in the rat small intestine and found in portal blood after hydrolysis by ceramidases in the gastrointestinal tract; nevertheless, a large proportion of ingested sphingolipids are excreted in the feces, and animal studies suggest that after oral intake, radiolabeled ceramides are metabolized, absorbed, and distributed to many tissues, including the skin.
Ueda et al. showed that orally administered radiolabeled D2-sphingosine is transferred to the skin, from dermis to epidermis in an unchanged structural form, and further generates radiolabeled glucosylceramides and ceramides by in vivo biosynthesis in mice. Dietary glucosylceramide derived from higher plants is only slightly absorbed by the intestine and is incorporated into ceramide structures in intestinal cells.
Orally administered plant glucosylceramides derived from rice and konjac can elevate epidermis ceramides by mechanisms including direct localization and use of absorbed dietary ceramides in the epidermis without any metabolism conversion, the use of exogenous GlcCer metabolites by keratinocytes to establish their own sphingolipids, or the generation of skin ceramides by metabolites. A proposed molecular mechanism involves the dietary sphingolipid fragments upregulating endogenous ceramide synthesis enzymes. Dietary sphingolipids significantly upregulated the expression of ceramide synthases 3 and 4 in the epidermis of the atopic dermatitis-like skin model.
In vitro prebiotic effects of glucosylceramide have been reported; using metabolome analysis followed by PLS-DA, adding glucosylceramide to the major intestinal bacterium Blautia coccoides had a significant metabolic effect, and glucosylceramide increased the number of Gram-positive bacteria through tolerance to deoxycholic acid. This mechanism is proposed as an indirect route by which dietary GlcCer may exert systemic physiological effects. A working hypothesis is that glucosylceramide passes through the small intestine, interacts with intestinal bacteria, increases the tolerance of these bacteria toward secondary bile acids, and decreases fecal hardness, and that these factors synergistically result in in vivo effects.
Studies in mice have correlated endogenous ceramides and glucosylceramides with the antagonism of insulin-stimulated glucose uptake and synthesis; in animal models of obesity, genetic or pharmacological inhibition of ceramide or glucosylceramide biosynthesis leads to increased peripheral insulin sensitivity while at the same time reducing the severity of pathologies associated with insulin resistance including diabetes, atherosclerosis, hepatic steatosis, and/or cardiomyopathy. These findings pertain to endogenous GlcCer overproduction in metabolic disease states rather than to dietary supplementation, and must be distinguished from supplementation evidence.
This is the most extensively studied application of dietary GlcCer supplementation, with multiple randomized controlled trials (RCTs) conducted primarily in Japanese populations.
Wheat-derived GlcCer (WPLC) — Human RCT: A placebo-controlled clinical study aimed to evaluate whether oral supplementation with glucosylceramides contained in a wheat polar lipids complex (WPLC) was able to improve skin conditions; sixty volunteers presenting dry and wrinkled skin were supplemented for 60 days with either a placebo or a WPLC extract in oil or powder form (1.7 mg GluCers and 11.5 mg of digalactosyldiglycerides), with skin parameters evaluated at baseline and after 15, 30, and 60 days. In this gold-standard study design, daily oral supplementation of purified wheat glucosylceramides and DGDG induced a strong and highly significant improvement in skin hydration markers compared to placebo after only 15 days and beyond; the level of efficacy on skin hydration and TEWL was higher and detected faster than data reported in other human clinical studies on sphingolipid or ceramide oral supplementation; and for the first time, anti-aging properties were demonstrated on four skin markers concomitantly: elasticity, smoothness, roughness, and wrinkledness.
Konjac-derived GlcCer — Human RCT: Skin health benefits of oral supplementation of a hydroalcoholic extract from Amorphophallus konjac tubers standardized to 5% glycosylceramides were assessed in a placebo-controlled trial; 51 healthy human volunteers (aged 18–60 years) were supplemented with 100 mg/day of either placebo or A. konjac extract capsules (5 mg glycosylceramides) for 6 weeks. Oral intake of A. konjac extract significantly decreased skin dryness, hyperpigmentation, redness, itching, and oiliness (p < 0.05), and the improvement in skin health was observed to be time-dependent from the start.
Konjac-derived GlcCer — Randomized double-blind human study: A randomized, double-blind, placebo-controlled study was conducted including 100 healthy subjects whose TEWL in cheek was relatively high. Clinical studies demonstrated that GlcCer reduced transepidermal water loss (TEWL), and a clinical trial was conducted on the effects of a rice-derived mixed fraction of GlcCer and β-sitosterol glucoside (Oryza Ceramide®) on TEWL and other skin parameters.
Golden mushroom-derived GlcCer — Human double-blind trial: A double-blind, placebo-controlled clinical trial involving 28 healthy participants evaluated the effects of Glumole-H® on skin conditions over a six-week period; participants were divided into two groups, with one receiving 40 mg/day of Glumole-H® and the other a placebo; key skin parameters including TEWL and skin surface conductance were measured at baseline, week 3, and week 6; results indicated that the Glumole-H® group exhibited a significant improvement in skin hydration, with TEWL values decreasing by 15% compared to baseline and by 18% relative to the placebo group, and skin surface conductance increased by 45% compared to the placebo group.
Wine lees-derived GlcCer — Human RCT (2024): A randomized, double-blind, placebo-controlled study was conducted with 30 healthy Japanese subjects aged 20–64; subjects received either the WLE-derived ceramides and glucosylceramides (test group) or placebo for 12 weeks, with the primary outcome being TEWL and secondary outcomes including skin hydration, itching sensation VAS, and the Japanese Skindex-29. The test group showed a tendency of lower TEWL compared to placebo after 8 weeks (p = 0.07), and after 12 weeks of administration, the test group had significantly lower TEWL than the placebo (p = 0.04).
Evidence strength — skin: The evidence base for skin barrier and hydration effects is the strongest of all GlcCer research areas, resting on multiple small-to-moderate RCTs. However, most trials have been conducted in Japan, in healthy populations, with short durations (6–12 weeks) and small sample sizes (28–100 participants). Independent replication in diverse populations, and larger-scale trials, are still needed. The beneficial effects of phytoCER-based oral dietary supplements for skin hydration and skin barrier reinforcement have been indicated in several studies involving animal models as well as human subjects.
Ceramides play a key role in the skin's barrier function, and an age-dependent decrease in ceramide content correlates with cutaneous clinical signs of dryness, loss of elasticity, and increased roughness. In 1991, a decrease in ceramide levels in the skin was proposed as the cause of atopic dermatitis. Animal research suggests a potential role for dietary GlcCer in atopic dermatitis (AD). The effects of dietary plant and yeast glucosylceramide on atopic dermatitis-like symptoms were investigated in a mouse model; after 7 weeks of feeding with a diet containing maize glucosylceramide, plasma IgE levels became significantly lower and, in contrast, the levels of interleukin-12 became significantly higher in the AD mice than in controls; however, the sphingolipid constituents of the skin fraction in the maize glucosylceramide-fed group did not contain sphingoid bases of plant origin, and the results indicated that dietary plant glucosylceramide prevented AD-like symptoms in AD model mice via regulation of Th1/Th2 balance. Oral intake of glycosylceramide reduces transepidermal water loss in normal adults or in atopic dermatitis patients. Evidence in human AD patients remains limited and indirect.
GlcCer facilitates improvements in intestinal impairments, lipid metabolism, and skin disorders, and sphingomyelin can exert both similar and different effects compared with those elicited by GlcCer. Evidence that diet and gut microbiome function can alter skin biology proposes an intriguing potential for the modulation of skin lipid homeostasis through gut microbial metabolism; sphingolipid synthesis by prominent gut microbes has been shown to affect intestinal, hepatic, and immune functions, with the potential for sphingolipid-producing bacteria to affect skin biology through altering skin sphingolipid levels.
In vitro and mechanistic data suggest GlcCer may act as a prebiotic. Glucosylceramide increased the number of Gram-positive bacteria through tolerance to deoxycholic acid, providing the first evidence of a mechanism underlying the action of glucosylceramide on intestinal microbes. However, this research has limitations, and adding pure components to monocultures does not necessarily reflect what occurs in the complex microbiota of the gut, since the actual gut is filled with various substances and microbes. No human clinical trials specifically targeting GlcCer's effects on the gut microbiome or intestinal permeability have been published.
Animal and in vitro evidence suggests GlcCer from dietary sources influences lipid metabolism. Dietary sea cucumber glucosylceramide decreased total cholesterol, increased the expression of the LDL receptor, and decreased the expression of CYP7A1 in mice. When a mixture of glucocerebrosides was administered as a diet supplement to rats, hepatic triglyceride and total cholesterol levels were reduced, as well as the activity of stearoyl-CoA desaturase, which is a key enzyme in the endogenous synthesis of fatty acids. These findings are animal data only; no published human RCTs have specifically targeted GlcCer supplementation for cholesterol or lipid outcomes.
This body of research relates primarily to endogenous GlcCer dysregulation rather than to dietary supplementation, and must be interpreted with care.
GlcCer is now recognized as a key molecule in cancer biology; while its dysregulation has long been associated with lysosomal storage disorders such as Gaucher disease, growing evidence implicates GlcCer in cancer initiation and progression, particularly within tumor-predisposing conditions. GlcCer modulates membrane microdomains, intracellular trafficking, and cell signaling, counteracting ceramide-induced apoptosis and promoting cellular survival; in cancer, aberrant upregulation of UGCG drives tumor growth, metastasis, and multidrug resistance through activation of PI3K/Akt, MAPK, Wnt/β-catenin, and NF-κB pathways.
Gaucher disease, an inborn error of metabolism, provides a relevant disease model. Gaucher disease is a multisystemic inherited metabolic disease that results from genetic alterations in the GBA gene leading to decreased β-glucosidase activity and subsequent accumulation of the substrate glucosylceramide in macrophages (known as Gaucher cells). An abundant literature points to the effects of glucosylceramide synthase, the mammalian enzyme that converts ceramide to β-glucosylceramide, in protecting tumor cells from chemotherapy; much less is known about the contribution of β-glucosylceramide and its breakdown products in cancer progression.
The lipid backbones of mammalian GlcCer (sphingosine, d18:1Δ4, and ceramide) induce cell death (apoptosis) and inhibit colon carcinogenesis. Research on dietary sphingolipids and colon cancer prevention at the preclinical level has been active. Around 2000, the use of dietary sphingolipids for the prevention of colon cancer was reported. These findings come from cell and animal studies; there are no human clinical trials of dietary GlcCer supplementation for cancer prevention or treatment.
The relationship between GlcCer and metabolic disease is complex and predominantly derived from research on endogenous, not supplemental, GlcCer. Gut microbes are linked to host metabolism, and ceramides, a type of sphingolipid, have been implicated in the development of a range of metabolic disorders from insulin resistance to hepatic steatosis. Treatment of genetically obese or diet-induced obese mice with highly specific glucosylceramide synthase inhibitors results in improved glucose tolerance and increased insulin sensitivity in muscle and liver; these studies strongly implicate a role for glycosylated ceramides in increased adipose tissue inflammation, peripheral insulin resistance, and hepatic steatosis. These pharmacological inhibitor studies are mechanistic in nature and do not directly pertain to dietary GlcCer supplementation.
The following dosages have been reported in published human studies:
No universal consensus or regulatory authority-established recommended daily intake exists for glucosylceramide as a dietary supplement.
No adverse events related to the supplements were reported in the WLE-derived ceramides and glucosylceramides trial; the authors concluded that oral supplementation of WLE-derived ceramides and glucosylceramides is a prominent and safe approach to enhancing skin barrier function and health.
In a preliminary study, WLE was assessed in a single-dose toxicity test on mice at 2000 mg/kg, and no adverse events were observed.
Wheat-derived glucosylceramide preparations are extracted from wheat polar lipids. Individuals with celiac disease or wheat allergy should exercise caution with such preparations, as their tolerance of residual wheat proteins or other wheat components in the extract cannot be assumed solely from the ceramide-fraction data. This concern is not well characterized in the clinical GlcCer literature.
The safety of dietary GlcCer supplementation in individuals with sphingolipid storage disorders (such as Gaucher disease, Niemann-Pick disease, or Fabry disease) has not been studied. Gaucher disease is caused by genetic alterations in the GBA gene leading to decreased β-glucosidase activity and subsequent accumulation of glucosylceramide in macrophages. Whether additional dietary GlcCer would exacerbate accumulation in enzyme-deficient individuals is not established by current evidence.
A large proportion of ingested sphingolipids are excreted in the feces; animal studies suggest that after oral intake, radiolabeled ceramides are metabolized, absorbed, and distributed to many tissues, including the skin. Dietary glucosylceramide derived from higher plants is only slightly absorbed by the intestine. The low absolute absorption rate may limit both efficacy and systemic adverse effects at typical supplemental doses.
While GlcCer dysregulation has long been associated with Gaucher disease, growing evidence implicates endogenous GlcCer in cancer initiation and progression; GlcCer modulates membrane microdomains, intracellular trafficking, and cell signaling, counteracting ceramide-induced apoptosis; in cancer, aberrant UGCG upregulation drives tumor growth, metastasis, and multidrug resistance through activation of PI3K/Akt, MAPK, Wnt/β-catenin, and NF-κB pathways. Whether pharmacologically relevant plasma levels of dietary GlcCer could influence these endogenous tumor-cell pathways is not established; currently published human data are restricted to skin barrier outcomes.
Synthetic ceramides are used generally as cosmetics; natural ceramides have drawn much attention during the recent past due to safety considerations, and plant-derived ceramides are chemically identical to those found in our skin. GlcCer derived from different foods has differences in its physiological effects, depending on the sphingoid backbone and constituent fatty acids, which implies that safety and efficacy data from one botanical source cannot be automatically extrapolated to another.
Condiciones de salud que Glucosilceramida puede ayudar a apoyar.
Glucosylceramide (glucocerebrosides) serve as precursors to skin ceramides and have been studied as oral and topical supplements for restoring the impaired ceramide-dependent skin barrier in atopic dermatitis. Plant-derived glucosylceramides show clinical evidence for improving skin barrier function and reducing dermatitis symptoms.
Glucosylceramide is a sphingolipid precursor to ceramides in the stratum corneum. Oral plant-derived glucosylceramide (from wheat, rice) has been studied in clinical trials showing improvements in skin moisture, TEWL reduction, fine lines, and skin smoothness. A 12-week RCT (NCT06083402) of wheat-oil glucosylceramides showed significant reductions in crow's feet wrinkles versus placebo.
Sistemas corporales que Glucosilceramida puede ayudar a apoyar.
Volver